Redx Pharma PLC (AIM:REDX) said a second drug from its pipeline has moved into phase II clinical trials following the recruitment of the first patient to its programme.
The 12-week study of RXC007 will assess for early signs of efficacy in people with a form of lung scarring called idiopathic pulmonary fibrosis (IPF).
Researchers will also carry out dose-ranging while looking closely at the tolerability and safety of the putative treatment.
The phase IIa evaluation, which is set to take 12 weeks to complete, will assess the impact of the RXC007 on people who have received the limited treatment options on offer to those with IPF and those who haven’t.
Headline data will be shared with the market in the second half of next year.
RXC007 is a ROCK2, or Rho Associated Coiled-Coil Containing Protein Kinase 2 selective inhibitor which Redx has designed to control fibrosis.